CSL Behring has identified what it will take to win in a major autoimmune market. Ahead of a potential approval of argenx’s rival drug, the company surveyed people with chronic inflammatory ...
The Melbourne-based company will build a 330,000-square-foot facility and retain 1,200 existing positions. Construction is ...
- 4- and 5-gram ZEMAIRA® vials may reduce the number of vials necessary for reconstitution, thereby providing convenience and lowering package waste KING OF PRUSSIA, Pa., Jan. 2, 2024 /PRNewswire/ -- ...
Narrow-moat CSL reiterated fiscal 2024 guidance for constant-currency group net profit after tax before amortization of USD 2.9 billion to USD 3.0 billion, implying 13%-17% growth on fiscal 2023. The ...
CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint in ...
Gov. Pritzker announced that global biotherapeutics firm CSL will invest nearly $1.5 billion to construct a new manufacturing ...
With plasma collection as its stock-in-trade, the struggles of CSL during the coronavirus lockdown were understandable. But a rebound—fueled by a surge in post-pandemic collections and an $11.7 ...
Stockhead on MSN
Dr Boreham’s Crucible: CSL’s tough diagnosis
A weak result and a sudden CEO departure have left CSL shares at eight-year lows. Management says the recovery plan ... Read ...
Both stocks have been hammered, but brokers see upside of 60% or more. The post Should you buy CSL and Pro Medicus shares today? appeared first on The Motley Fool Australia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results